RET and non-small cell lung carcinoma: ARROW is the first prospective study to investigate pralsetinib for the treatment of RET fusion-positive NSCLC and in an updated analysis from the trial, ORR was 62% (95% CI 53–70) in patients who had received prior platinum therapy (n = 126) and 73% (95% CI 50–89) in those who had received prior non-platinum therapy (n = 22); The median PFS was 16.5 and 12.8 months, respectively (Griesinger et al., 2022).